Medical devices

The European market is attractive for medical device manufacturers. However, manufacturers should be aware that it is a moving target. Substantial changes have been recently introduced in the European regulatory framework for medical devices and further change is expected in the upcoming years. Concurrently, national health authorities, facing rising health costs, tend to grow more fussy about reimbursement issues. These trends translate into a greater demand of clinical evidence of device performance and safety. While many see this as a burden it is also an opportunity for innovators to make their product stand out from the rest and obtain rewarding reimbursement rates. The aim of this site is to present, in a set of brief and practical documents, the European context and to explain how ClinSearch can help you to choose and implement the best strategy for a successful marketing in Europe.

Our services for your devices

ClinSearch is committed to helping you market your device in Europe and obtain a fair reimbursement by performing any necessary clinical evaluation or investigation.

  • Counselling on clinical evaluation strategy
  • Bibliographic review and meta-analysis
  • Analysis, reporting and publishing of existing data
  • Controlled clinical trials
  • Observational studies: cohorts and registries
  • Diagnostic accuracy studies
  • Medico-economic evaluations

Top five reasons to perform clinical evaluation

  1. In the new European regulatory framework for medical devices, some sort of clinical evaluation is required for the registration of new devices.
  2. Your device is innovative and you believe this results in a tangible benefit for patients. Demonstrating it by an appropriately designed clinical investigation will allow you to obtain a higher price or reimbursement.
  3. Should your device raise a safety issue, you will learn it early enough to take corrective action. You will thus avoid damage to your company’s reputation by a paper in a medical journal or worse, in the news, and lawsuits that may altogether be fatal to your business.
  4. If, on the other hand, your device is safe, by documenting this safety you will be in position to counter unwarranted claims of harm.
  5. By allowing selected investigators to experiment with your device and to contribute to a good scientific paper you will raise the level of trust of these physicians and their readers in your product.

Further reading

Let clinical evidence
support innovation

Follow us: LinkedIn Twitter rss

Applications

Sample size / continuous outcome Sample size / binary outcome Sample size / time-to-event outcome

News

Morning Read: Non-profit designing free Wi-Fi architecture for hospitals >> Read

Managing retinal vein occlusion >> Read

Let Me Die on the Prairie by Frances Jane Crosby Van Alstyne >> Read

Publication: Volume 16, number 4 (Stevenson). Study found that no conclusive results can be provided on the cost-effectiveness of four non-invasive tests for liver fibrosis [the Enhanced Liver Fibrosis Test, FibroTest and FibroMAX and transient elastography (FibroScan)] in patients suspected of having alcohol-related liver disease. >> Read

Top headlines from HIMSS2012 (Tuesday edition) >> Read

Incidence of diabetic retinopathy in people with type 2 diabetes mellitus attending the Diabetic Retinopathy Screening Service for Wales: retrospective analysis >> Read

Publication: Volume 16, number 3 (Hockenhull). Report finds that whilst some interventions targeted at mental health populations to reduce violence are well supported by the evidence a scattergun approach in the research literature provides little firm evidence for the majority of interventions. Evidence shows small-to-moderate effects for cognitive behavioural therapy for psychological interventions, and larger effects for atypical antipsychotic drugs. >> Read

How the NHS measures up to other health systems >> Read

Publication: Volume 16, number 5 (Ara). Although orlistat, sibutramine and rimonabant are all effective at reducing weight and body mass index and, compared with placebo, are all cost-effective, both sibutramine and rimonabant have been withdrawn because of safety concerns relating to potential treatment-induced fatal adverse events. >> Read

Peter John Fenton >> Read

Publication: Volume 16, number 6 (Reeves). The verteporfin photodynamic therapy cohort study found that treatment and follow-up were much less frequent in routine clinical practice than in research trials and the cost-effectiveness was similar to the highest previous estimate. >> Read

Frederick Valentine Flynn >> Read